找货集市
扫码去集市看看
买家服务
卖家服务
关于我们
7*24在线客服
客服
智能助手
AI助手
系统消息
消息
扫码进入小程序
小程序
搜索
快速询价
快速询价
收藏
欧盟就活性物质醚菌胺的农药风险评估发布同行评审
营养素制造网
2023-11-02
1
#原料快讯
内容摘要
核心提示:据欧盟食品安全局(EFSA )消息,2023年10月30日,欧盟食品安全局就活性物质醚菌胺(dimoxystrobin)的农药风险评估发布同行评审。……(世界食品网-www.shijiesh...

核心提示:据欧盟食品安全局(EFSA )消息,2023年10月30日,欧盟食品安全局就活性物质醚菌胺(dimoxystrobin)的农药风险评估发布同行评审。……(世界食品网-www.shijieshipin.com)

据欧盟食品安全局(EFSA )消息,2023年10月30日,欧盟食品安全局就活性物质醚菌胺(dimoxystrobin)的农药风险评估发布同行评审。

经过评估,将醚菌胺作为杀菌剂用在油菜和向日葵的基础上,欧盟食品安全局提出了适用于监管风险评估和建议的最大残留限量的可靠端点,列出了监管框架要求的缺失信息,在确定的地方提出问题。部分原文报道如下:

The conclusions of the EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State, Hungary, and co-rapporteur Member State, Ireland, for the pesticide active substance dimoxystrobin as well as the assessment of maximum residue levels (MRLs) and confirmatory data following the review of the existing MRLs of dimoxystrobin according to Article 12 of Regulation (EC) No 396/2005 are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. In June 2023, the European Commission sent a mandate confirming the need to adopt and publish a conclusion on the peer review of the pesticide risk assessment of the active substance dimoxystrobin excluding the full assessment of endocrine-disrupting properties, containing all the results of the peer review process related to the renewal of approval as well as the assessment of the application for MRL for oilseed rapeseed, poppy seed, mustard seed and gold of pleasure seed, and the MRL application addressing the confirmatory data identified during the MRL review under Article 12 of Regulation (EC) No 396/2005. The conclusions were reached on the basis of the evaluation of the representative uses of dimoxystrobin as a fungicide on oilseed rape and sunflower. MRLs were assessed in rapeseeds, poppy seed, mustard seed and Gold of pleasure seed. The reliable end points, appropriate for use in regulatory risk assessment and the proposed MRLs, are presented. Missing information identified as being required by the regulatory framework is listed. Concerns are presented where identified.